Candel Therapeutics, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.38 M

Shareholding (Mar 2025)

FII

2.33%

Held by 22 FIIs

DII

60.5%

Held by 30 DIIs

Promoter

10.10%

How big is Candel Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Candel Therapeutics, Inc. has a market capitalization of 247.51 million and reported net sales of 0.00 million with a net profit of -39.58 million over the last four quarters. Shareholder's funds were 66.33 million, and total assets were 107.14 million as of Dec 24.

What does Candel Therapeutics, Inc. do?

22-Jun-2025

Candel Therapeutics, Inc. is a micro-cap company in the miscellaneous industry, reporting a net profit of $7 million for Q1 2025 and a market cap of $247.51 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -45.06%.

Is Candel Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 28, 2025, Candel Therapeutics, Inc. is in a mildly bearish trend, supported by bearish indicators like the MACD and moving averages, despite some bullish signals from the KST, and has underperformed the S&P 500 with a year-to-date return of -43.09%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Miscellaneous

Market cap

USD 280 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.02

Return on Equity

-39.06%

Price to Book

3.10

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

3.04%

6 Months

-8.52%

1 Year

16.63%

2 Years

484.51%

3 Years

179.79%

4 Years

-44.04%

5 Years

0.0%

Candel Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Candel Therapeutics, Inc. technically bullish or bearish?

As of 28 August 2025, the technical trend for Candel Therapeutics, Inc. has changed from sideways to mildly bearish. The current stance is bearish, with key indicators supporting this view including a bearish MACD on the weekly timeframe and a bearish moving average on the daily timeframe. The Bollinger Bands also indicate a mildly bearish trend on the weekly and a bearish trend on the monthly. Although the KST shows bullish signals on both weekly and monthly timeframes, it is outweighed by the bearish signals from other indicators. In terms of performance, the stock has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -43.09% versus the S&P 500's 12.22%....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-3.15%

EBIT Growth (5y)

-179.98%

EBIT to Interest (avg)

-24.62

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.09

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

57.05%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.05

EV to EBIT

-6.58

EV to EBITDA

-6.78

EV to Capital Employed

-32.35

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-45.06%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 20 Schemes (27.07%)

Foreign Institutions

Held by 22 Foreign Institutions (2.33%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 78.38% vs -131.25% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.90",
          "val2": "-8.30",
          "chgp": "-31.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.60",
          "chgp": "-66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "5.70",
          "val2": "-13.30",
          "chgp": "142.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.80",
          "val2": "-22.20",
          "chgp": "78.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -45.65% vs -101.60% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-32.40",
          "val2": "-37.20",
          "chgp": "12.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.10",
          "val2": "2.60",
          "chgp": "-19.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-20.80",
          "val2": "1.00",
          "chgp": "-2,180.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-55.20",
          "val2": "-37.90",
          "chgp": "-45.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-10.90

-8.30

-31.33%

Interest

0.20

0.60

-66.67%

Exceptional Items

5.70

-13.30

142.86%

Consolidate Net Profit

-4.80

-22.20

78.38%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 78.38% vs -131.25% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-32.40

-37.20

12.90%

Interest

2.10

2.60

-19.23%

Exceptional Items

-20.80

1.00

-2,180.00%

Consolidate Net Profit

-55.20

-37.90

-45.65%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -45.65% vs -101.60% in Dec 2023

All Annual Results

Company CV

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc.

Miscellaneous

No Details Available.

Company Coordinates

No Company Details Available

Candel Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Candel Therapeutics, Inc.?

Watch in Real-Time

What does Candel Therapeutics, Inc. do?

Is Candel Therapeutics, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Candel Therapeutics, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Candel Therapeutics, Inc.

Company Coordinates